DR. MATHEW ROBERT MEENEGHAN M.D. NPI 1467695460

NPI Details

DR. Mathew Robert Meeneghan, M.D. is a hematology and oncology internal medicine in Bastrop, TX with 16 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Mathew Robert Meeneghan, M.D. NPI is 1467695460. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
Graduation Year:2009

The provider's business location address is:

3107 HIGHWAY 71 E
BASTROP, TX
ZIP 78602-158
Phone: (512) 308-9024
Fax: (512) 308-9074

The NPI 1467695460 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection of drug or substance into vein (HCPCS:96374)
• Vitamin d-3 level (HCPCS:82306)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Folic acid level, serum (HCPCS:82746)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Red blood count, automated test (HCPCS:85045)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Drawing of blood for a medical problem (HCPCS:99195)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)

The enumeration date for this NPI number is 4/7/2009 and was last updated on 1/20/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.